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Objective: This study aimed to assess risk factors for developing marginal ulcer (MU) after gastric bypass (GBP) surgery for obesity.
Summary Background Data: MU is a common and potentially serious complication of GBP surgery, little is known about its etiology. 
Methods: This population-based cohort study of GBP in 2006-2011 evaluated MU in relation to diabetes, hyperlipidemia, hypertension, chronic obstructive pulmonary disease (COPD), ulcer history, use of proton pump inhibitors (PPIs), aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and selective serotonin re-uptake inhibitors (SSRIs). Multivariable Cox proportional hazard regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for confounding. 
Results: Among 20,294 GBP patients, diabetes and peptic ulcer history entailed statistically significantly increased risk of MU (HR=1.26, 95%CI 1.03-1.55 and HR=2.70, 95%CI 1.81-4.03), while hyperlipidemia, hypertension and COPD did not. PPI users had an increased HR of MU (HR=1.37, 95%CI 1.17-1.60). Aspirin and NSAID consumption ≤median entailed decreased HRs of MU (HR=0.56, 95%CI 0.37-0.86 and HR=0.30, 95%CI 0.24-0.38), while aspirin and NSAID users >median had an increased risk and no association with MU, respectively (HR=1.90, 95%CI 1.41-2.58 and HR=0.90, 95%CI 0.76-1.87). SSRI use ≤median had a decreased risk of MU (HR=0.50, 95%CI 0.37-0.67), while use >median entailed increased HR (HR=1.26, 95%CI 1.01-1.56). 










This population-based cohort study included all patients in Sweden who underwent GBP for obesity between January 1, 2006 and December 31, 2011 according to the Swedish Patient Registry. This register provides data on all hospitalizations with diagnoses and surgical procedures in Sweden since 1987. The exposure diagnoses diabetes, hyperlipidemia, hypertension, COPD, and ulcer history as well as the outcome diagnosis MU, were defined by the codes given in the International Classification of Diseases (ICD) versions 7-10. Surgical procedures were classified according to the Nordic Medico-Statistical Committee (NOMESCO, Swedish version, 1997), and the codes that defined laparoscopic and open GBP were JDF11 and JDF10, respectively. The Swedish Patient Registry has a 85-95% validity of diagnoses in general  ADDIN EN.CITE 17, and codes representing upper gastrointestinal surgery have been shown to have up to 99.6% positive predictive value  ADDIN EN.CITE 18. Data on drug use were retrieved from the Swedish Prescribed Drug Registry, which was initiated in July 1, 2005. This register records all prescribed and dispensed drugs in the entire Swedish population (approximately 9.5 million inhabitants) ADDIN EN.CITE 19. The register contains information on names of prescribed drug substances according to the anatomical therapeutic chemical (ATC) classification, and it also contains individual data on what amounts of the drug-specific Defined Daily Dose (DDD) that has been dispensed. Data on mortality and migration were collected from the National Registry of the Total Population, which provides complete information on updated dates of birth, death and migration in Sweden with a maximum of 14 days delay. This information enabled censoring of person-time no longer at risk of MU in the cohort due to death or emigration. All registers used in this study contain personal identity numbers, a 10-digit identifier assigned to all Swedish residents, which enabled all linkages of individuals in the study cohort to register data. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden.


Definition of the study exposures
Among the nine study exposures, five were the diagnoses diabetes, hyperlipidemia, hypertension, COPD (used as a proxy for tobacco smoking), and history of peptic ulcer, which were recorded in the Patient Registry before or at the time of GBP surgery. The remaining four exposures were use of the medications PPI, aspirin, NSAID and SSRI, as recorded in the Prescribed Drug Registry. The following codes were used to identify the study exposures:
1.	Diabetes was defined by ICD7 codes 260, ICD8 code 250, ICD9 codes 249-250 and ICD10 codes E10.0 – E14.9.
2.	Hyperlipidemia was defined by the ICD8 code 272, the  ICD9 code 272, the ICD10 code E78 and also identified by use of lipid lowering agents defined as dispensed prescriptions of drugs with ATC-code C10.
3.	Hypertension was defined by the ICD7 codes 444-447, ICD8 codes 400-404, ICD9 code 401 and ICD10 codes I10-I15.
4.	COPD was defined by the ICD7 code 502, the ICD8 codes 491-492, the ICD9 codes 491-492 and the ICD10 codes J44.0-J44.9.
5.	History of peptic ulcer was defined by the ICD7 codes 540-541, the ICD8 codes 531-533, the ICD9 codes 531-533 and the ICD10 codes K25-K27.
6.	Use of PPI was defined by dispensed prescriptions of drugs with ATC-codes A02BC and A02BD.
7.	Use of aspirin was defined by dispensed prescriptions of drugs with ATC-code B01AC.
8.	Use of other NSAIDS was defined by dispensed prescriptions of drugs with ATC-codes M01AB, M01AC, M01AE and M01AH.
9.	Use of SSRI was defined by dispensed prescriptions of drugs with ATC-code N06AB.

To achieve statistical power, NSAIDs other than aspirin were analyzed as one group, since they have similar effects and indications. In Sweden, aspirin is mainly prescribed as primary or secondary prophylaxis for circulatory diseases. 

Definition of marginal ulcer
The study outcome was a diagnosis of MU, as recorded in the Patient Registry. We used two definitions for MU, which were analyzed separately. First, we used a broad definition, including the code for ulcer at the gastro-entero anastomosis (for gastro-jejunal ulcer) and the codes for peptic ulcer in general (IDC10 codes K25-K28). Secondly, we used a narrow definition of MU, only including the specific code for gastro-jejunal ulcer (ICD10 code K28). 

Statistical analysis
Cox proportional hazard regression models were used to estimate the relative risk between the study exposures and MU, presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Absence of the studied exposure was used as reference category. Multivariable models were created to adjust for age (below or equal to median or above median), sex (male or female), and exposure status of all other nine study variables (yes or no). Sensitivity analysis was performed combining the GBP with obesity diagnosis (ICD10 code E66) with the purpose of excluding any patients undergoing GBP for other reasons than obesity, e.g. incurable gastric cancer or peritoneal metastases. Follow-up continued until a diagnosis of MU, death, emigration or end of study period (December 31 2011), whichever occurred first. Two analysis approaches were utilized to assess drug use: 1) At least one prescribed and dispensed prescription of the drug from 100 days before GBP surgery until end of follow-up (categorized into yes or no), and 2) amount of exposure based on defined daily dose (DDD), expressed as sum of DDD divided by follow-up time. Among study subjects with prescriptions of the study drugs, the median amount was calculated based on the total amount of the drug the patients collected during the study period. Study subjects with no collected prescription of the drug were assigned to a separate group of non-users, and thus not included in calculation of the median use. 





In total, 20,924 patients who underwent GBP were included in the study cohort and the mean follow-up time was 2 years. Basic characteristics of all GBP patients the 694 GBP patients (3.3%) who developed MU are shown in Table 1. There were no major differences in the sex or age distribution between all patients and those who developed MU, but open surgery was overrepresented compared to laparoscopic surgery among patients with MU (26%) versus those in the total cohort (14%). The frequencies of the nine study exposures differed between the total cohort and the MU patients as presented in Table 1. 

Medical conditions and risk of marginal ulcer
Among patients with diabetes, the adjusted HR of MU was 26% increased (HR 1.26, 95% CI 1.03-1.55) (Table 2). Patients with hyperlipidemia, hypertension, or COPD (proxy for smoking) did not have any statistically significantly increased risk of MU (HR 1.20, 95% CI 0.95-1.59, HR 1.17, 95% CI 0.97-1.43, and HR 0.56, 95% CI 0.26-1.17, respectively). Patients with a history of peptic ulcer disease experienced a strongly increased HR of MU (HR 2.70, 95% CI 1.81-4.03) (Table 2). 

Use of medication and risk of marginal ulcer





This study indicates that diabetes and a history of ulcer are risk factors for MU after GBP surgery for obesity, while hyperlipidemia, hypertension and COPD are not. PPI use might not strongly decrease the risk of MU. Limited doses of aspirin, NSAIDs, or SSRIs do not seem to increase the risk of MU, while higher doses of aspirin seem to increase this risk. 

Among strengths of this study are the population-based design, the large sample size, the completeness of follow-up, and the availability of several potential risk exposures that enabled adjustments for potential confounding. Moreover, the register data used are valid and complete, which guarantee robust identification of exposures and outcomes with minimal missing data or loss to follow-up. There are also several limitations. There might be some level of misclassification in the coding of MU. To assess any influence of such misclassification, we analyzed both standard peptic ulcer codes and the specific code for ulcer after gastro-jejuno-anastomosis, and the similar results argue against major influence of misclassification of the outcome. As in any observational study, influence of residual confounding by factors not adjusted for cannot be dismissed. Direct data on smoking and H. pylori status were not available in the registers, nor were data on body mass index (BMI). However, we did adjust the results for COPD, as proxy for tobacco smoking. The vast majority of patients suffering from COPD are tobacco smokers, typically with a long period of smoking history. The misclassification of the exposure to smoking among COPD patients should therefore be limited. We also adjusted for history of peptic ulcer, which might be regarded as a proxy for H. pylori. Another concern in non-randomized studies of drug use is confounding by indication (protopathic bias)  ADDIN EN.CITE 20, and it is possible that use of the four drug exposures was influenced by the reasons for its use. Furthermore, some drugs obtained over the counter cannot be taken in to account, particularly regarding NSAIDs, but long-term use is typically based on prescriptions, which counteracts influence of over the counter use. This source of error should be limited and random, and might therefore only slightly dilute risk estimates. However, aspirin for circulatory diseases is not sold over the counter in Sweden, and results for these drugs were similar.

Regarding the association between diabetes and MU, the results from previous studies diverge. A US study of 103 GBP surgery patients found an increased risk of MU among patients with diabetes, whereas another US study of 763 operated patients and an earlier Danish study of 260 patients found no such association  ADDIN EN.CITE , , . The present study, based on many more GBP surgery patients, does suggest a role of diabetes in the etiology of MU, which should not be dismissed. 

Peptic ulcer history has, to the best of our knowledge, not previously in a large population-based setting been investigated in relation to risk of MU. The strongly increased risk for MU in the present study is therefore particularly interesting. The mechanism underlying this association is not clear, but it may reflect an impact of H. pylori infection. A Danish study found that 32% of MU patients were infected with H. pylori, compared to 12% of controls  ADDIN EN.CITE 11, and a Belgian study showed better treatment effect of PPI use among H. pylori positive MU patients compared to non-infected MU patients  ADDIN EN.CITE 13. However, other studies have found no support for H. pylori being a risk factor for MU  ADDIN EN.CITE , . It is possible that a subgroup of patients with MU have H. pylori infection with ulcers that behave more like regular peptic ulcers, and thus are easier to treat with standard regimens  ADDIN EN.CITE 13. 





The hypothesis that hyperlipidemia is a risk factor for MU has been addressed in only two previous studies, both showing no association with MU  ADDIN EN.CITE , . This is consistent with the findings of the present study. 

Two US studies have indicated that tobacco use might be a risk factor for MU  ADDIN EN.CITE , . In our study using COPD as proxy for smoking, no increased risk of MU was found. However, there were few patients with COPD in our study and the exposure was only an indirect measure of smoking, why this finding must be interpreted cautiously. 

Regarding PPI, a single-centre study comprising 2,535 GBP patients found an incidence of 2.3% MU after administrating routine prophylactic treatment with PPI to all patients 90 days after surgery, and 44% of the patients with MU needed surgical intervention, which suggests that PPI treatment is not effective in preventing MU or its complications. Another single-centre study found that prophylactic treatment with PPI did not influence the risk of MU among patients who tested negatively for H. pylori prior to surgery, but reduced the risk of MU among preoperatively H. pylori positive patients  ADDIN EN.CITE 13. There was no clear association between PPI use and MU in the present study. The increased risk among users of high doses of PPI might be due to confounding by indication with reverse cause and effect, particularly since there are no reasons to believe that such PPI use would increase the risk of MU. Since patients with symptoms of MU are likely to use PPI for their epigastric discomfort before the MU diagnosis is confirmed, the outcome probably precedes the exposure in this study. Yet, taken together with previous research, it seems likely that PPI is less effective in the treatment of MU compared to peptic ulcer disease. 

This study revealed no clearly increased risk of MU following treatment with low doses of aspirin or NSAID, while higher doses of aspirin seem to increase this risk. As opposed to other NSAIDS, aspirin causes an irreversible and unselective inhibition of the cyclooxygenase (cox) enzyme and following suppression of prostaglandin synthesis. This prolonged damaging effect on the mucosa might partly explan the difference between the two groups. In the NSAIDs group, a lesser amount of more selective cox-2 inhibitors were also included, which could also account for some differences. As mentioned, OTC NSAIDs is not accounted for in this study. Although this is not, as explained, so much of an issue for aspirin, we cannot exclude that OTC consumption in the group we defined as non-users could slightly dilute the results for NSAIDs. The seemingly protective effects of low doses of these drugs might speculatively be due to their anti-inflammatory and anti-coagulant properties. Another potential explanation is confounding by indication, since pain caused by MU might lead to an increased use of analgetics like NSAIDs. Use of aspirin and other NSAIDs is a well-established risk factor for peptic ulcer disease, but has not been proven to increase the risk of MU  ADDIN EN.CITE , , although some studies contradict this  ADDIN EN.CITE 21. The results of the present study seem to support the notion that low doses of aspirin and NSAIDs are not strong risk factors for MU. 


Use of SSRIs has not previously been investigated in relation to risk of developing MU. As in the case of aspirin and NSAIDs, it is possible that the anticoagulant properties of low doses of SSRI might have a limited protective effect, but more research is needed to make any conclusions about this potential association.
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